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¤¤
¤¤
¤ Background: Long-term peritoneal dialysis (PD) is asso-
ciated with the development of various structural and func-
tional changes to the peritoneal membrane when
bioincompatible conventional peritoneal dialysis fluids
(PDFs) are used. In this study, we looked at patients that
were treated with conventional PDFs and then changed to
novel biocompatible PDFs with a neutral pH and a low con-
centration of glucose degradation products (GDPs) to in-
vestigate whether this change could result in the arrest or
reversal of peritoneal membrane deterioration.
¤¤
¤¤
¤ Methods: In an open label, randomized prospective trial,
the clinical effects of conventional PDFs and biocompatible
PDFs with neutral pH and very low concentration of GDPs
were compared in 104 patients equally divided between both
study PDFs. Blood and effluent dialysate samples, perito-
neal equilibration tests, and adequacy evaluation were un-
dertaken at baseline, 4, 8, and 12 months. The target
variables were the ratio of dialysate-to-plasma (D/P) creat-
inine, peritoneal ultrafiltration, residual renal function,
dialysis adequacy indices, and effluent cancer antigen 125
(CA125).
¤¤
¤¤
¤ Results: D/P creatinine values were not different in the
two groups. Peritoneal ultrafiltration was significantly
higher in the low-GDP PDF group than in the conventional
PDF group at all follow-up times (4 months: 9.1 ± 4.3 vs
6.0 ± 3.0; 8 months: 8.3 ± 3.4 vs 6.0 ± 3.0; 12 months: 8.9 ±
3.3 vs 6.1 ± 3.3 mL/g dextrose/day; p < 0.05). Peritoneal
Kt/V urea values and total weekly Kt/V urea values at
4 months were significantly higher in the low-GDP PDF group
than in the conventional PDF group. Residual renal func-
tion was not statistically significant. Effluent CA125 levels
were significantly higher in the low-GDP PDF group at all
follow-up visits (4 months: 37.8 ± 20.8 vs 22.0 ± 9.5;
8 months: 41.2 ± 20.3 vs 25.9 ± 11.3; 12 months: 40.4 ±
21.4 vs 28.6 ± 13.0 U/mL; p < 0.05). Among anuric patients,
peritoneal ultrafiltration at 4, 8, and 12 months, total
weekly Kt/V at 4 and 8 months, and CA125 levels at all fol-
low-up visits were significantly higher in patients treated
with low-GDP PDF than those treated with conventional PDF.
However, among anuric patients, D/P creatinine showed no
significant differences between the low-GDP PDF group and
the conventional PDF group.
¤¤
¤¤
¤ Conclusion: The use of biocompatible PDFs with neutral
pH and low GDP concentration can contribute to improve-
ment of peritoneal ultrafiltration and peritoneal effluent
CA125 level, an indicator of peritoneal membrane integrity
in PD patients.
Perit Dial Int 2008; 28:174–182 www.PDIConnect.com
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Peritoneal dialysis (PD) has been an important part ofrenal replacement therapy over the past 20 years. Al-
though a number of studies have reported similar pa-
tient survival rates for PD and hemodialysis, all of those
studies indicated lower technique survival rates for PD
than for hemodialysis (1–5). Ultrafiltration (UF) failure
remains a major cause of technique failure in patients
treated with PD; the incidence of UF failure increases with
PD duration because of acquired changes in peritoneal
membrane function (6–13). The peritoneal membrane
may be compromised by the development of various
structural and functional alterations occurring during
the course of long-term PD treatment. There is increas-
ing evidence that repeated exposure to conventional
peritoneal dialysis fluids (PDFs) plays a role in the de-
velopment of peritoneal membrane changes (13,14).
Conventional PDFs are bioincompatible because of their
low pH, high glucose and lactate concentrations, hyper-
osmolality, and the presence of glucose degradation
products (GDPs) formed during heat sterilization of the
solutions. Recently, there has been increased interest
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sition of each PDF is shown Table 1. After being randomly
assigned to L-GDP PDF or C-PDF groups, all patients un-
derwent an initial 4-week run-in phase. Subjects began
the study phase, which provided for three additional as-
sessment investigations at 4-month intervals, after the
run-in phase (Figure 1).
A medical history was taken and a physical examina-
tion performed, which included mean arterial blood
pressure, body mass index (BMI; kg/m2), and nutritional
status assessed by a Subjective Global Assessment (SGA)
scale using a 7-point scoring system. This assessment
was repeated at 4 months, 8 months, and 12 months. At
in the effect of glucose exposure on the peritoneal
membrane’s dialytic function. The alteration in dialytic
function may be due to either the direct effects of glu-
cose itself or to the GDPs formed during heat steriliza-
tion of the solutions. Absorption of GDPs from the
peritoneal cavity may contribute to the generation of
circulating carbonyl compounds, resulting in the accel-
eration of systemic advanced glycation end-product
(AGE) formation and local AGE modification of perito-
neal membrane structures, which is believed to be a
major contributing factor to changes in membrane func-
tion (15–21). Therefore, low-GDP PDF may preserve peri-
toneal integrity and thus improve the longevity of the
peritoneal membrane.
In a previous publication, we reported improved
patient survival following the introduction of one
such PDF (balance; Fresenius Medical Care, St. Wendel,
Germany) in Korea (22). The aim of this current pro-
spective study is to investigate the impact of novel
PDFs with neutral pH and low GDP concentration on
peritoneal solute and fluid transport characteristics,
as well as on other biochemical and clinical param-
eters in PD patients.
METHODS
PATIENTS
A total of 126 PD patients in Yonsei University Sever-
ance Hospital were recruited. Each patient gave written
informed consent before study entry; the local ethics
committee gave approval for the study. Only patients that
maintained continuous ambulatory PD (CAPD) with con-
ventional PDFs for at least 6 months prior and were con-
sidered to be adequately dialyzed were enrolled. Patients
used three or four 1.5- to 2.5-L exchanges per day, 7 days
per week. Patients with dialysis-related complications
(e.g., CAPD peritonitis, exit-site infection, tunnel infec-
tion) within the previous 8 weeks or with more than
2 episodes of peritonitis within the previous 6 months
were excluded. Twenty-two patients were excluded prior
to the baseline study because of screening failure. The
remaining 104 patients, after being assigned to a group,
underwent a baseline study.
STUDY PROCEDURES AND MATERIALS
This was an open randomized prospective study with
two parallel groups, comparing a conventional PD solu-
tion (C-PDF group) with a novel, neutral pH, low GDP
concentration solution (balance; Fresenius Medical Care,
Bad Homburg, Germany; L-GDP PDF group). The compo-
TABLE 1
The Composition of Each Study Solution
Low-GDP Conventional
PDF PDFa
Sodium (mmol/L) 134 134
Calcium (mmol/L) 1.75 1.75
Magnesium (mmol/L) 0.5 0.5
Chloride (mmol/L) 101.5 103.5
Lactate (mmol/L) 35 35
Bicarbonate (mmol/L) 2 0
pH 7 5.5
Glucose (anhydrous; g/L) 15–42.5 15–42.5
3-deoxyglucosone (m mol/L) 42–60 172–324
Methylglyoxal (m mol/L) <1 6–10
Acetaldehyde (m mol/L) <2 152–182
Formaldehyde (m mol/L) <3 7–13
GDP = glucose degradation product; PDF = peritoneal dialysis
fluid.
a Conventional PDFs were made by Baxter Healthcare (Dianeal),
Fresenius Medical Care (stay·safe), and Boryung Korea.
Figure 1 — The flow diagram of this study design and number
of patients at each visit. PD = peritoneal dialysis; CAPD = con-
tinuous ambulatory PD; PET = peritoneal equilibration test;
PDFs = peritoneal dialysis fluids; GDP = glucose degradation
product.
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the same times, blood and dialysate effluent samples
were taken and the peritoneal equilibration test (PET)
and adequacy evaluation were performed. Blood samples
were analyzed for total venous CO2, hemoglobin, albu-
min, calcium, phosphorus, total cholesterol, and
C-reactive protein (CRP).
Peritoneal membrane function was evaluated by stan-
dard PET using a 2.5% glucose PD solution (23). Adequacy
was calculated as Kt/V urea and creatinine clearance
(L/week/1.73 m2). These values were measured by col-
lecting all of the dialytic effluent over a 24-hour period
and taking a plasma sample during the PET. Residual
renal function was evaluated by collecting all urine out-
put over the same 24-hour period as the dialysate col-
lection. Residual renal function (glomerular filtration
rate; mL/minute) was calculated as the mean of renal
urea and creatinine clearances.
Peritoneal UF, measured at each visit, was calculated
as the difference in prescribed fill volume and measured
drain volume over a 24-hour period. Ultrafiltration was
adjusted for the prescribed dextrose load of PDF (UF as
mL/g dextrose load per day). Creatinine clearance was
standardized to a body surface area of 1.73 m2, while
urea clearance was expressed as Kt/V.
At the end of the 4-week run-in phase (0 months) and
at the time points 4 months, 8 months, and 12 months,
peritoneal effluent was collected from a timed overnight
dwell  (10 hours), using a 2.5% overnight drain. Approxi-
mately 50 mL of overnight drain fluids was collected and
filtered, and 5-mL aliquots were stored at –70°C prior
to assay in a single laboratory. Effluent CA125 was mea-
sured using an electrochemiluminescence immunoassay
(Roche Diagnostics, GmbH, Mannheim, Germany) and
CRP was measured by nephelometry (Dade Behring,
Germany).
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS version
13.0 (SPSS, Chicago, Illinois, USA). Simple comparisons
between L-GDP PDF and C-PDF groups were made using
an unpaired t-test. For a longitudinal view of the study,
we analyzed the data by repeated-measures analysis of
variance (ANOVA). This test was performed separately
for each group. Change in D/P creatinine and change in
peritoneal UF were calculated as percentage changes
from the baseline values. Values are expressed as mean ±
standard deviations. For display purposes, box and whis-
ker plots were used. The median value is indicated within
the box, each box including 50% of the values (the inter-
quartile range), with the bars representing the highest
and lowest values, excluding outliers and extreme val-
ues. A value of p < 0.05 was considered statistically
significant.
RESULTS
BASELINE CLINICAL CHARACTERISTICS, PERITONEAL
FUNCTION AND ADEQUACY, RESIDUAL RENAL FUNCTION
In the L-GDP PDF group, 13 patients exited the study
due to peritonitis (n = 3), transplantation (n = 1), death
due to causes unrelated to PD (n = 3), and withdrawal of
informed consent for this study (n = 6) (L-GDP PDF group
at 0 months: n = 51; 4 months n = 47; 8 months n = 44;
12 months n = 38). In the C-PDF group, 23 patients dis-
continued due to peritonitis (n = 2), death due to causes
unrelated to PD (n = 3), and voluntary switch to the low-
GDP PD solution (n = 18) (C-PDF group at 0 months: n =
53; 4 months: n = 49; 8 months: n = 47; 12 months:
n = 30).
Baseline clinical characteristics of the two groups are
shown in Table 2. Age, mean arterial pressure, propor-
tion of diabetic patients, proportion of anuric patients,
and PD duration were not significantly different between
the two groups.
Actual D/P creatinine was not statistically different
between the L-GDP PDF group and the C-PDF group
(0 months: 0.67 ± 0.11 vs 0.67 ± 0.10; 4 months: 0.66 ±
0.10 vs 0.65 ± 0.10; 8 months: 0.67 ± 0.10 vs 0.66 ± 0.11;
12 months: 0.66 ± 0.10 vs 0.66 ± 0.11; p = NS). Change in
D/P creatinine also showed no significant differences
(Figure 2) between the two groups.
Dextrose loading of PDFs (g/day) was not different
between the two groups. Peritoneal UF was significantly
higher in the L-GDP PDF group than in the C-PDF group
at all follow-up visits (Table 3). Peritoneal UF adjusted
for dextrose load (UF as milliliters per gram dextrose
load) was significantly higher in the L-GDP PDF group
than in the C-PDF group at all follow-up visits (0 months:
7.5 ± 3.5 vs 6.3 ± 3.1, p = 0.073; 4 months: 9.1 ± 4.3 vs
6.0 ± 3.0; 8 months: 8.3 ± 3.4 vs 6.0 ± 3.0; 12 months:
8.9 ± 3.3 vs 6.1 ± 3.3 mL/g dextrose; p < 0.05). Change
in peritoneal UF was significantly higher at 12 months
in the L-GDP PDF group than in the C-PDF group
(4 months: 33.1 ± 60.9 vs 21.8 ± 126.8, p = 0.580;
8 months: 19.5 ± 60.4 vs 15.0 ± 88.2, p = 0.776;
12 months: 25.8 ± 50.2 vs –12.6 ± 99.7, p < 0.05)
(Figure 3).
Peritoneal Kt/V urea and total weekly Kt/V urea at
4 months were significantly higher in the L-GDP PDF group
than in the C-PDF group (peritoneal Kt/V urea: 1.92 ± 0.37
vs 1.73 ± 0.30; total weekly Kt/V urea: 2.02 ± 0.39 vs
1.84 ± 0.33; p < 0.05), whereas renal Kt/V urea was not
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different between the two groups. Peritoneal, renal, and
total weekly creatinine clearance values were not sig-
nificantly different between the two groups (Table 3).
There were no significant differences in residual renal
function, change in residual renal function (Figure 4),
or urine volume between the two groups (Table 3).
EFFLUENT CA125 LEVELS
Effluent CA125 levels were significantly higher in the
L-GDP PDF group at all follow-up visits during the
12 months (4 months: 37.8 ± 20.8 vs 22.0 ± 9.5;
8 months: 41.2 ± 20.3 vs 25.9 ± 11.3; 12 months: 40.4 ±
TABLE 2
Baseline Clinical Characteristics and Biochemical Parameters in Low-GDP PDF Group and Conventional PDF Group
Low-GDP PDF group (n=51) Conventional PDF group (n=53) p Value
Gender (male:female) 20:31 27:26 0.230
Age (years) 52.6±12.4 55.4±11.9 0.235
BMI (kg/m2) 24.5±3.4 24.3±3.3 0.843
SGA 6.0±0.7 6.1±0.9 0.907
MAP (mmHg) 103.0±13.0 100.6±14.7 0.385
DM (yes:no) 9:42 10:43 0.872
PD duration (months) 67.0±46.7 70.4±45.8 0.709
Anuric patients (yes:no) 32:19 34:19 0.882
Hemoglobin (g/dL) 9.7±1.5 9.6±1.4 0.746
Calcium (mg/dL) 9.4±1.0 9.5±0.9 0.664
Phosphorus (mg/dL) 5.0±1.0 5.1±1.3 0.902
Fasting glucose (mg/dL) 100.1±23.7 107.2±37.4 0.254
Total protein (g/dL) 6.3±0.4 6.3±0.6 0.829
Albumin (g/dL) 3.6±0.3 3.5±0.4 0.356
Total cholesterol (mg/dL) 190.7±45.2 187.0±37.2 0.655
Total CO2 (mmol/L) 24.7±3.6 25.1±3.3 0.602
CRP (mg/dL) 0.3±0.4 0.5±0.4 0.068
GDP = glucose degradation product; PDF = peritoneal dialysis fluid; BMI = body mass index; SGA = Subjective Global Assessment;
MAP = mean arterial pressure; DM = diabetes mellitus; PD = peritoneal dialysis; CRP = C-reactive protein.
Data are expressed as number of patients and mean±SD. The number of patients was tested by chi-square and means by unpaired
t-test. p Values compare Low-GDP PDF group to Conventional PDF group.
Figure 2 — Box plots of dialysis-to-plasma ratio of creatinine (D/Pcr; left panel) and change in D/P creatinine ( D D/Pcr; right
panel) for low-GDP PDF group and conventional PDF group. GDP = glucose degradation product; PDF = peritoneal dialysis fluid.
Low-GDP PDF group Conventional PDF group Low-GDP PDF group Conventional PDF group
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21.4 vs 28.6 ± 13.0 U/mL; p < 0.05). Repeated-measures
ANOVA comparing data from baseline (0 months) and
other study visits revealed a significant increase in ef-
fluent CA125 levels within the L-GDP PDF group (p <
0.05). Mean effluent CA125 levels increased from
21.7 U/mL at 0 months to 37.8 U/mL at 4 months,
41.2 U/mL at 8 months, and 40.4 U/mL at 12 months. In
the C-PDF group, there were no significant differences
in effluent CA125 levels throughout the study (Table 3).
OTHER CLINICAL AND BIOCHEMICAL PARAMETERS
The CRP levels in the L-GDP PDF group were lower than
those in the C-PDF group. The L-GDP PDF group main-
TABLE 3
Peritoneal Adequacy, Dextrose Loads of PDFs, Effluent CA125 Levels, and Urine
Volume in Low-GDP PDF Group and Conventional PDF Group
Low-GDP PDF group Conventional PDF group
0 months 4 months 8 months 12 months 0 months 4 months 8 months 12 months
Peritoneal Kt/V urea 1.8±0.3 1.9±0.4a 1.8±0.3 1.8±0.3 1.70±0.3 1.7±0.3 1.7±0.39 1.7±0.3
Renal Kt/V urea 0.1±0.3 0.1±0.2 0.1±0.2 0.1±0.2 0.1±0.3 0.1±0.2 0.1±0.2 0.04±0.1
Total weekly Kt/V urea 1.9±0.4 2.0±0.4a 1.9±0.4 1.9±0.4 1.9±0.4 1.8±0.3 1.8±0.3 1.8±0.3
Peritoneal ClCr 49.2±7.0 51.3±9.0 49.3±7.4 48.7±6.0 48.3±6.3 49.8±8.8 48.0±6.2 48.3±6.2
Renal ClCr 7.9±17.7 5.7±11.0 4.9±10.9 4.7±10.7 8.9±22.9 5.7±11.0 5.2±9.5 1.86±6.44
Total ClCr 55.2±15.2 65.5±58.1 54.3±11.9 53.2±10.8 55.9±22.8 55.5±11.5 52.0±11.6 50.2±8.0
nPNA 0.9±0.2 0.9±0.2 1.0±0.2 0.9±0.2 0.9±0.2 0.9±0.2 0.9±0.2 0.9±0.2
Dextrose load (g/day) 145.1±38.3 146.1±31.4 145.0±29.2 151.4±54.5 155.7±44.3 160.6±43.0 159.8±43.7 167.3±38.8
UF (mL/day) 1110.8±555.2 1281.9±618.2a 1204.5±585.4a 1301.3±597.6a 921.2±498.0 954.1±542.7 922.3±496.7 981.7±538.8
Effluent CA125 (U/mL) 21.7±16.7 37.8±20.8a,b 41.2±20.3a,b 40.4±21.4a,b 21.2±10.5 22.0±9.5 25.9±11.3 28.6±13.0
Urine volume (mL/day) 385.5±330.7 272.6±217.8 215.3±222.5 280.0±236.6 447.1±278.4 383.7±272.0 362.5±332.1 143.0±172.9
PDF = peritoneal dialysis fluid; CA125 = cancer antigen 125; GDP = glucose degradation product; ClCr = creatinine clearance (L/week/
1.73 m2); nPNA = normalized protein equivalent of nitrogen appearance; UF = ultrafiltration.
a p < 0.05: Low-GDP PDF group versus Conventional PDF group.
b p < 0.05: baseline CA125 values versus those in other visit.
Data are expressed as mean±SD. The means at each visit were tested by unpaired t-test.
Figure 3 — Box plots of peritoneal ultrafiltration (UF; left panel) and change in peritoneal ultrafiltration (D UF; right panel) for
low-GDP PDF group and conventional PDF group (mL/g dextrose load/day). GDP = glucose degradation product; PDF = peritoneal
dialysis fluid.
Low-GDP PDF group Conventional PDF group Low-GDP PDF group Conventional PDF group
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tained significantly lower CRP levels than the C-PDF
group (Table 4). SGA was significantly higher in the L-GDP
PDF group at 12 months than in the C-PDF group, while
BMI was not different between the groups. Other bio-
chemical parameters, such as total venous CO2, hemo-
globin, albumin, calcium, phosphorus, and total
cholesterol, were not significantly different between the
groups (Table 4).
ANURIC PATIENTS
The number of anuric patients (voided 0 mL of urine
per day) was 32 in the L-GDP PDF group and 34 in the
C-PDF group at 0 months. Peritoneal UF in anuric patients
of the L-GDP PDF group was significantly higher than in
anuric patients of the C-PDF group at 4, 8, and 12 months
(0 months: 7.4 ± 3.1 vs 6.6 ± 3.9, p = 0.34; 4 months:
TABLE 4
Clinical and Biochemical Parameters in Low-GDP PDF Group and Conventional PDF Group
Low-GDP PDF group Conventional PDF group
0 months 4 months 8 months 12 months 0 months 4 months 8 months 12 months
BMI (kg/m2) 24.5±3.4 24.3±3.4 25.0±3.5 25.3±3.3 24.3±3.3 24.6±3.3 24.6±3.4 25.5±3.7
SGA 6.0±0.7 5.9±0.8 6.1±0.8 6.4±0.7a 6.1±0.9 5.8±0.9 6.0±0.8 5.9±0.8
Hemoglobin (g/dL) 9.7±1.5 10.0±1.2 10.0±1.2 9.5±1.9 9.7±1.4 9.6±1.2 9.9±1.2 10.1±1.1
Calcium (mg/dL) 9.4±1.0 9.6±1.1 9.6±0.9 9.8±1.0 9.5±0.9 9.6±0.9 9.7±0.8 9.8±0.7
Phosphorus (mg/dL) 5.0±1.0 4.9±1.1 5.1±1.2 5.2±1.2 5.1±1.3 5.2±1.3 5.3±1.3 5.3±1.4
Fasting glucose (mg/dL) 100.1±23.7 100.7±26.6 102.0±32.1 100.1±24.1 107.2±37.4 101.4±29.3 101.0±26.5 102.4±25.1
Total protein (g/dL) 6.3±0.4 6.3±0.5 6.3±0.5 6.3±0.5 6.3±0.6 6.4±0.7 6.3±0.6 6.7±5.4
Albumin (g/dL) 3.6±0.3 3.5±0.3 3.5±0.3 3.5±0.3 3.5±0.4 3.6±0.4 3.5±0.4 3.7±0.4
Total cholesterol (mg/dL) 190.7±45.2 189.1±47.7 178.0±32.0 18.51±38.9 187.0±37.2 185.3±31.2 180.7±32.9 180.3±53.7
Total CO2 (mmol/L) 24.7±3.6 24.4±2.8 25.0±2.4 23.8±4.0 25.1±3.3 25.5±3.1 25.6±2.5 23.8±4.2
CRP (mg/dL) 0.32±0.35 0.30±0.28a 0.28±0.48a 0.33±0.36a 0.46±0.41 0.74±1.15 0.59±0.79 0.59±0.67
GDP = glucose degradation product; PDF = peritoneal dialysis fluid; BMI = body mass index; SGA = Subjective Global Assessment;
CRP = C-reactive protein.
a p Values < 0.05 compare Low-GDP PDF group versus Conventional PDF group.
Data are expressed as mean±SD. The means at each visit were tested by unpaired t-test.
Figure 4 — Box plots of residual renal function (RRF; left panel) and change in residual renal function ( D RRF; right panel)
for low-GDP PDF group and conventional PDF group (mL/min). GDP = glucose degradation product; PDF = peritoneal dialy-
sis fluid.
Low-GDP PDF group Conventional PDF group Low-GDP PDF group Conventional PDF group
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on O
ctober 28, 2014
http://w
w
w
.pdiconnect.com
/
D
ow
nloaded from
 
180
CHOI et al. MARCH 2008 – VOL. 28, NO. 2 PDI
8.7 ± 3.9 vs 6.5 ± 2.8; 8 months: 8.5 ± 3.5 vs 6.4 ± 2.9;
12 months: 8.9 ± 4.1 vs 6.5 ± 2.2 mL/g dextrose; p <
0.05). The L-GDP PDF group had significantly higher peri-
toneal Kt/V than the C-PDF group at 4 and 8 months
(0 months: 1.8 ± 0.3 vs 1.7 ± 0.3, p = 0.24; 4 months:
2.0 ± 0.4 vs 1.7 ± 0.3; 8 months: 1.9 ± 0.3 vs 1.8 ± 0.3;
p < 0.05). Effluent CA125 levels in the L-GDP PDF group
were significantly higher at all follow-up visits than in
the C-PDF group (0 months: 22.1 ± 14.6 vs 19.0 ± 8.9, p =
0.31; 4 months: 40.7 ± 24.6 vs 21.1 ± 9.1; 8 months:
42.3 ± 21.8 vs 26.1 ± 12.1; 12 months: 41.8 ± 20.3 vs
29.9 ± 14.7 U/mL; p < 0.05). Peritoneal creatinine clear-
ance and D/P creatinine showed no differences between
the groups.
DISCUSSION
We performed a randomized prospective study with
parallel arms to demonstrate the clinical effects of a
novel, neutral pH, low GDP concentration PDF on perito-
neal membrane function and other biochemical param-
eters, compared to conventional lactate-buffered PDF.
We found no statistically significant differences in D/P
creatinine or in change of D/P creatinine. Rippe et al.
also demonstrated no significant differences in perito-
neal transport characteristics by the assessment of un-
restricted pore area over unit diffusion path length
(“area parameter”: for small solute transport; A0 /D x)
among patients treated with conventional PDFs and low-
GDP PDFs (24,25). The Euro-Balance Trial group, how-
ever, reported D/P creatinine to be higher in patients
treated with low-GDP PD solution (26).
Previous reports show varying results of peritoneal
UF in PD patients treated with low-GDP PD solutions. In
the Euro-Balance Trial, a decrease in peritoneal UF in was
reported in their low-GDP PDF treatment group (26).
However, the present study demonstrated that perito-
neal UF was significantly higher in the L-GDP PDF group
than in the C-PDF group at all follow-up visits. Net peri-
toneal UF was adjusted according to dextrose load, which
was calculated from all four bags during 24 hours. The
changes in peritoneal UF were more significant in the
L-GDP PDF group than in the C-PDF group. The exact
mechanisms for this difference are unclear. One hypoth-
esis was postulated that, because subjects in this study
had been maintained on CAPD for more than 6 years by
the beginning of the study (L-GDP PDF group:
67.0 months; C-PDF group: 70.4 months), the character-
istics of the peritoneal membrane could have changed
during the long duration of treatment with CAPD. There-
fore, the responses to the conversion from bioincompat-
ible conventional PDFs to low-GDP PDFs may have been
different from those in the Euro-Balance Trial. However,
the Bicarbonate/Lactate Study Group demonstrated a
statistically significant increase in mean net 24-hour
peritoneal UF during the 6-month treatment period ver-
sus baseline in the bicarbonate/lactate PD solution treat-
ment group (27). They also found that mean glucose
concentration calculated from all four bags was relatively
constant over the 6 months that UF measurements were
made. In a subgroup analysis of anuric patients in the
Euro-Balance Trial, membrane function, as assessed by
D/P creatinine and peritoneal UF, showed no significant
differences between the groups, although there was a
tendency for UF to decrease over the course of the study
in the Balance group (26). Our data demonstrated no
significant difference in D/P creatinine among anuric
patients treated with either PDF. However, the anuric
patients in the L-GDP PDF group showed significantly
higher peritoneal UF values than the C-PDF group.
Previous clinical trials of low-GDP PDFs showed no sig-
nificant changes in Kt/V urea, as shown by urea clear-
ance (27). The Euro-Balance Trial group revealed
inconsistent results in changes in Kt/V in the group
treated with Balance PDF (26). In our study, peritoneal
Kt/V urea was significantly higher in the L-GDP PDF group
at 4 months than in the C-PDF group. This difference was
magnified among anuric patients and found to be
present at 4 and 8 months. However, these effects of
urea clearance were concealed at following visits. Con-
trary to urea clearance, creatinine clearance was not dif-
ferent between the two groups. This might imply that
low-GDP PDF treatment could cause substantial en-
hancement of peritoneal UF along with removal of small
molecules.
In the present study, residual renal function and urine
volume showed no significant differences between the
two groups. However, the number of patients that main-
tained urine volume during the 12-month study period
was too small, raising the possibility of a type II error.
Cancer antigen 125 levels were consistently higher in
the L-GDP PDF group at all follow-up visits during the
12-month period. First described by Visser et al., CA125
has been well-established as a marker of mesothelial cell
mass and turnover in in vitro and in vivo studies (28–33).
In a previous study, longitudinal follow-up of CA125 lev-
els in peritoneal effluent showed a negative trend over
the course of PD. CA125 can be used to monitor the in-
tegrity of the mesothelium in PD patients (30). The me-
sothelium is thought to influence the kinetics of PD. After
a few years on PD, the mesothelium is degraded due to
repeated episodes of peritonitis and accumulating cyto-
toxicity driven by either glucose or GDPs in the PDF
(34,35). All the PD patients in the present study had al-
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ready been exposed to conventional PDFs, so their CA125
levels were similar upon beginning our study. Using
ANOVA for repeated measures, CA125 levels within the
L-GDP PDF group increased significantly from baseline
values, while those in the C-PDF group remained stable.
These higher effluent CA125 levels may imply that
healthy mesothelial cell physiology could be restored
with the use of novel, low GDP concentration PDFs.
Previous studies of biocompatible PDFs were associ-
ated with decreased interleukin-6 synthesis and vascu-
lar endothelial growth factor secretion. These data
suggest that the biocompatible PDFs are associated with
reduced intraperitoneal inflammation and reduced po-
tential for angiogenesis (36,37). The higher levels of CRP
in the C-PDF group at all follow-up visits may reflect an
increase in chronic inflammation among PD patients
treated with conventional PDFs compared to those
treated with the novel PDFs in this study.
In conclusion, the present study compares the clini-
cal impact of novel, low GDP concentration, biocom-
patible PDFs with conventional PDFs. We compared
peritoneal function and other biochemical parameters
such as effluent CA125 and CRP. The use of biocompatible
PDFs with neutral pH and low GDP concentration may
contribute to improvement of peritoneal ultrafiltration
and increase peritoneal effluent CA125, a marker of peri-
toneal membrane integrity. This may preserve peritoneal
solute transport in PD patients, including those with
anuria.
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